[go: up one dir, main page]

WO2004089274A1 - Conditionnement de medicaments ou kit, ou presentation facilitant l'auto-administration de medicaments par les patients - Google Patents

Conditionnement de medicaments ou kit, ou presentation facilitant l'auto-administration de medicaments par les patients Download PDF

Info

Publication number
WO2004089274A1
WO2004089274A1 PCT/BR2004/000047 BR2004000047W WO2004089274A1 WO 2004089274 A1 WO2004089274 A1 WO 2004089274A1 BR 2004000047 W BR2004000047 W BR 2004000047W WO 2004089274 A1 WO2004089274 A1 WO 2004089274A1
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
kit
drug
self administration
fact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2004/000047
Other languages
English (en)
Inventor
Alexandre FUNARI NEGRÃO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medley Farmaceutica Ltda
Original Assignee
Medley Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medley Farmaceutica Ltda filed Critical Medley Farmaceutica Ltda
Publication of WO2004089274A1 publication Critical patent/WO2004089274A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers

Definitions

  • the present invention refers to a drug packaging, or kit, or presentation of drugs that facilitates self administration by patients, applicable to the pharmaceutical industry, primarily intended for the treatment of people with problems related to gastroesophageal dysfunctions such as functional dyspepsia, associated with the gastroesophageal reflux disease, among others.
  • Functional dyspepsia is quite a common clinical condition, mostly characterized by epigastric pain in the absence of ulcerous lesions or other possibly related diseases. Other symptoms also present include abdominal discomfort or distention, reflux esophagitis, nausea, vomiting, and early satiation.
  • a drug packaging, or kit, or drug presentation facilitating self administration of drugs by patients has been developed, based on a treatment method for dyspeptic symptom incidence which consists of the administration to the patients of one or more prokinetic and/or antiemetic drugs, and of one or more gastric acid inhibitors, and other drugs well-known to those skilled in the art.
  • an improved functionality item i.e., a drug packaging, or kit, or drug presentation facilitating self administration of drugs by the patients, which is characterized by comprising one or more blister cards, cartridges, blisters, or the like, each one presenting one or more proton pump inhibitor (PPI) drug units, and one or more prokinetic and/or antiemetic drug units, or yet other drugs well-known to those skilled in the art, featuring patient instructions in print form with regard to the dosage of each unit, type or nature of the active ingredient, period of the day to be taken and treatment period, among other information, or according to FIGURE 1 or FIGURE 2 in annex.
  • PPI proton pump inhibitor
  • the gastric acid inhibitors or proton pump inhibitors are a class of anti- secretory compounds that suppresses gastric acid secretion by specific inhibition of the (H+, K+) ATPase enzyme system at the secretory surface of the gastric parietal cells.
  • the proton pump inhibitor (PPI) drugs used can be selected from the group containing: lansoprazole, omeprazole, pantoprazole, esomeprazole magnesium, rabeprazole sodium, among others, or their mixtures and combinations, in multiple dosages.
  • Lansoprazole is preferably used at the dosages of 15 mg or 30 mg.
  • the prokinetic and/or antiemetic drugs that can be used are selected from the group containing: bromopride, metoclopramide, domperidone, cisapride, alizapride hydrochloride, among others, or their mixtures and combinations, in multiple dosages, preferably that of 10 mg per drug unit. Particularly, bromopride is used at the unit dosage of 10 mg.
  • Bromopride is a prokinetic agent that also acts as an antiemetic agent by inhibiting the brain's vomiting center. Its therapeutic effect consists of normalizing stomach, duodenum and jejunum motility by restoring muscle tone and peristalsis to physiological standards
  • Unit of drug or drug unit implies tablets, pastilles, capsules, pills, or the like.
  • Each blister card, or cartridge, or blister, or the like features in a clear, instructive manner, instructions in print form about the drugs to be taken according to the time period, preferable of 7 days, identifying separately or individually per day, units to be administered or ingested at each period of the day, as for example: before breakfast, before lunch, and before dinner.
  • the drug packaging, or kit, or presentation facilitating self administration of the drugs by the patients contains enough drug units for 14, or 28 days, for a longer term treatment, comprising 2 or 4 blister cards, or cartridges, or blisters, or the like, each one presenting 7 proton pump inhibitor (PPI) drug units and 21 prokinetic and/or antiemetic drug units, didactically arranged so that the daily dosage be obeyed.
  • PPI proton pump inhibitor
  • lansoprazole is used as a proton pump inhibitors (PPI), at the dosages of 15 mg or 30 mg and bromopride as a prokinetic at the dosage of 10 mg.
  • FIGURES 1 and 2 in annex represent a possible model of the invention.
  • This comprises a blister card with drugs showing its front side (1) and its back side (2), which contain information in print form for a better orientation and utilization of these drugs by the patient, such as: - the names of the active ingredients involved: bromopride 10 mg (3) and lansoprazole 15 mg (4);
  • - treatment periodicity in this case for a week or 7 days; - it presents an individual distribution of drug units, indicating, horizontally, the units to be taken per day: 1 st day (5), 2 nd day (6), 3 rd day (7), 4 th day (8), 5 th day (9), 6 th day (10), and 7 th day (11); - it presents distinct columns, identified by different colors, indicating the drug units to be ingested:
  • the drug units are shown individualized and on the back side (2) instructions are shown, as composed in table below:
  • FIGURES 2 and 3 in annex represent another possible model of the invention.
  • This comprises a blister card with drugs showing its front side (1) and its back side (2), which contain information in print form for a better orientation and utilization of these drugs by the patient, such as:
  • the drug units are shown individualized and on the back side (2) instructions are shown, as composed on the table below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)

Abstract

La présente invention porte sur un conditionnement de médicaments ou kit, ou une présentation facilitant l'auto-admnistration de médicaments par les patients, qui se caractérise en ce qu'il comprend une plusieurs plaquettes alvéolaires, cartouches, blisters ou analogue, chacun présentant un ou plusieurs unités de médicament d'inhibiteur de pompe à protons (PPI), et une ou plusieurs unités de médicament procinétique et/ou antiémétique, ou d'autres médicaments bien connus par rapport à ceux de la technique antérieure, comportant des instructions imprimées relatives au dosage de chaque unité, du type ou de la nature de l'ingrédient actif, à l'heure de prise du médicament et à la période de traitement, parmi d'autres informations.
PCT/BR2004/000047 2003-04-09 2004-03-31 Conditionnement de medicaments ou kit, ou presentation facilitant l'auto-administration de medicaments par les patients Ceased WO2004089274A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR8300543U BR8300543U (pt) 2003-04-09 2003-04-09 Embalagem, ou kit de medicamentos, ou apresentação facilitadora da administração de medicamentos por parte dos pacientes
BRMU8300543-9 2003-04-09

Publications (1)

Publication Number Publication Date
WO2004089274A1 true WO2004089274A1 (fr) 2004-10-21

Family

ID=33136652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2004/000047 Ceased WO2004089274A1 (fr) 2003-04-09 2004-03-31 Conditionnement de medicaments ou kit, ou presentation facilitant l'auto-administration de medicaments par les patients

Country Status (2)

Country Link
BR (1) BR8300543U (fr)
WO (1) WO2004089274A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093021A1 (fr) * 2006-02-17 2007-08-23 Bayer Healthcare Ag Conditionnement ou kit de médicaments ou présentation pour l'administration régulière de médicaments pour le traitement de l'hypertension, de l'angor et d'autres maladies cardiovasculaires.
WO2011113440A1 (fr) 2010-03-18 2011-09-22 Futurelogix Aps Système d'ouverture d'un emballage médical alvéolaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132771A (en) * 1996-01-08 2000-10-17 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132771A (en) * 1996-01-08 2000-10-17 Astrazeneca Ab Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093021A1 (fr) * 2006-02-17 2007-08-23 Bayer Healthcare Ag Conditionnement ou kit de médicaments ou présentation pour l'administration régulière de médicaments pour le traitement de l'hypertension, de l'angor et d'autres maladies cardiovasculaires.
WO2011113440A1 (fr) 2010-03-18 2011-09-22 Futurelogix Aps Système d'ouverture d'un emballage médical alvéolaire
US8459458B2 (en) 2010-03-18 2013-06-11 Medcomb Holding Aps Disposable rigid container for pharmaceutical compositions
US8991607B2 (en) 2010-03-18 2015-03-31 Medcomb Holding Aps System for opening a medical blister package
US9901512B2 (en) 2010-03-18 2018-02-27 Medcomb Holding Aps System for opening a medical blister package

Also Published As

Publication number Publication date
BR8300543U (pt) 2004-11-23

Similar Documents

Publication Publication Date Title
ES2315299T3 (es) Envase de producto medicinal para la terapia de erradicacion.
WO2000066082A1 (fr) Compositions et methodes antinauseeuses
WO1982003551A1 (fr) Composition et procede de traitement d'alcooliques et de toxicomanes
EP2385769A1 (fr) Formulation de vitamines se dissolvant rapidement et procédés d'utilisation de celle-ci
EP2094253A1 (fr) Compositions de paracétamol à effets indésirables réduits, y compris une hépatotoxicité réduite
JP6511492B2 (ja) 女性胃不全麻痺に関係する症状の処置
US20250144121A1 (en) Compositions and methods for treating multiple sclerosis
US20080181937A1 (en) Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard)
US20190388370A1 (en) Treatment of symptoms associated with female gastroparesis
WO2004089274A1 (fr) Conditionnement de medicaments ou kit, ou presentation facilitant l'auto-administration de medicaments par les patients
Gordon Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
WO2015059638A2 (fr) Combinaison du stimulant de snc et d'antagoniste de récepteur d'opioïdes comme traitement anti-obésité non addictif, non aversif et synergique
SHIPLEY et al. A double-blind cross-over trial of indomethacin, fenoprofen and placebo in ankylosing spondylitis, with comments on patient assessment
JP2001509791A (ja) 胃腸障害の治療用組成物及び方法
US20080090879A1 (en) Method of treatment
US20140155435A1 (en) Kit for Treatment of Upper Gastrointestinal Tract Conditions
Khanna et al. A Systematic Review on Vonoprazan Fumarate Used in the Treatment of GERD
US20050043359A1 (en) Kit for treatment of upper gastrointestinal tract conditions
SULLIVAN Esophagectomy Deaths Not Tied to Case Volume
Mitrea Pharmacology
Grennan et al. The Pharmacoeconomics of Proton Pump Inhibitors Prescribing in Ireland
Graedon et al. Dangerous Drug Interactions: How to Protect Yourself from Harmful Drug/drug, Drug/food, Drug/vitamin Combinations
Agent Sandoz Loperamide
TH32076A (th) รูปขนาดใช้ยาทางเภสัชกรรมสำหรับให้ทางปาก ซึ่งประกอบด้วยสารยับยั้งการดึงโปรตอน และสารโปรไคเนทิค
Aniwan et al. Effects of Chili on Abdominal Pain, Abdominal Burning and Rectal Sensation in Diarrhea Predominate Irritable Bowel Syndrome (IBS-D)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase